ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

Autoři	KOESSLER T. ALSINA M. ARNOLD D. BEN-AHARON I. COLLIENNE M. LUTZ M. P. NEUZILLET C. OBERMANNOVÁ Radka PEETERS M. SCLAFANI F. SMYTH E. VALLE J. W. WAGNER A. D. WYRWICZ L. FONTANA E. MOEHLER M.
Rok publikování	2022
Druh	Článek v odborném periodiku
Časopis / Zdroj	ESMO OPEN
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.esmoop.2022.100392
Klíčová slova	oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer
Popis	There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.